SHARE: +/-: 0.00 SEK / Bid: 14.75 SEK / Ask: 15.50 SEK / Price: 15.50 SEK / High: 15.80 SEK / Low: 14.80 SEK / Quantity: 3 717 / Turnover: 56 878 SEK / 2019-12-13 16:28 (CET)
 

Press releases

First patient dosed in the SPAGOPIX-01 study

The first patient in the clinical study SPAGOPIX-01 has been successfully dosed with the contrast agent SN132D and completed MRI.   The clinical study SPAGOPIX-01 is conducted at the Uppsala University Hospital in Sweden and will include up to 20 patients with with confirmed breast cancer. The primary objective is…
Read more

Spago Nanomedical has initiated the clinical trial SPAGOPIX-01

Spago Nanomedical AB (publ) has conducted site initiation visit at the Uppsala University Hospital in Uppsala and formally opened the first clinical trial with the tumor selective contrast agent SpagoPix (SN123D). The trial will include up to 20 patients with confirmed breast cancer.   The primary objective with the trial…
Read more

Spago Nanomedical to present preclinical data for SpagoPix at ECR

Spago Nanomedical AB (publ) will present preclinical data for SpagoPix at the conference European Congress of Radiology (ECR) this week The presentation, in the form of a poster with the title ”Efficacy and safety profile of SN132D, a novel nanoparticle MRI contrast agent”, includes preclinical data that collectively show that…
Read more

Spago Nanomedical receives approval to initiate the clinical trial SPAGOPIX-01

Spago Nanomedical AB (publ) has received approval from the Swedish Medical Products Agency to initiate the first clinical trial with the contrast agent SpagoPix (SN132D) in patients with breast cancer. SpagoPix is a nanomedical contrast agent with potential to significantly improve cancer diagnostics with magnetic resonance imaging (MRI). Spago Nanomedical…
Read more

New data on SpagoPix published in European Journal of Inorganic Chemistry

Study results show that the signal strength of SpagoPix is among the highest reported for MRI contrast agents and far higher than those of the clinically used gadolinium based contrast agents currently in clinical use. The article, titled ”Characterization of a manganese-containing nanoparticle as MRI contrast agent”, is the result…
Read more

Spago Nanomedical submitted application for initiation of the phase I clinical trial SPAGOPIX01

Spago Nanomedical AB (publ) applied today with the Swedish Medical and Pharmaceutical Agency for initiation of a phase I clinical trial of the contrast agent SpagoPix (SN132D) in patients with breast cancer. The study is planned to be conducted in Sweden at Uppsala University Hospital. The intention is to start…
Read more

Tumorad® patent granted in Europe

Spago Nanomedical AB (publ) announce today that the European Patent Office (EPO) has granted the company´s patent application comprising product protection for Tumorad®. Tumorad® is based on nanoparticles loaded with a radioisotope and holds potential to become a new treatment of cancer. Earlier this year the patent was approved in…
Read more

US patent granted for Tumorad®

Spago Nanomedical AB (publ) announce today that the United States Patent and Trademark Office (USPTO) has granted the company´s patent application comprising product protection for Tumorad® in the USA.
Read more

Spago Nanomedical select CTC for the first clinical trial with SpagoPix

Spago Nanomedical AB has signed an agreement with the Swedish clinical CRO CTC Clinical Trial Consultants AB for the conduct of the first clinical study with SpagoPix.
Read more

SpagoPix shows good safety in regulatory preclinical studies

Spago Nanomedical AB (publ) has completed the in-life part of the regulatory preclinical program with SpagoPix. The product candidate SN132D displays a good safety margin to clinically relevant doses.
Read more